Clinical Benefits of Early Concurrent Use of Cryoprecipitate and Plasma Compared With Plasma Only in Bleeding Trauma Patients. Issue 10 (17th July 2022)

• Record Type: Journal Article
• Authors: Endo, Akira; Senda, Atsushi; Otomo, Yasuhiro; Firek, Matthew; Kojima, Mitsuaki; Coimbra, Raul
• Is Part Of: Critical care medicine. Volume 50:Issue 10(2022)
• Page Start: 1477
• Page End: 1485
• Publication Date: 2022-07-17
• Subjects: cryoprecipitate -- fibrinogen -- hemorrhagic shock -- resuscitation -- transfusion; Critical care medicine -- Periodicals; Soins intensifs -- Périodiques; 616.028
• DOI: 10.1097/CCM.0000000000005596
• Languages: English
• ISSNs: 0090-3493

Abstract

Abstract : OBJECTIVES: The effectiveness of cryoprecipitate (Cryo) in trauma has not been well established; the benefits of Cryo might have been overestimated in previous studies since the difference in the total amount of administered clotting factors was not considered. We aimed to evaluate the benefits of the concurrent use of Cryo in combination with fresh frozen plasma (FFP) for bleeding trauma patients. DESIGN: Retrospective cohort study. SETTING: The American College of Surgeons Trauma Quality Improvement Program database between 2015 and 2019. PATIENTS: Patients who received greater than or equal to 5 units of packed RBCs and at least 1 unit of FFP within the first 4 hours after arrival to a hospital were included and dichotomized according to whether Cryo was used within the first 4 hours of hospital arrival. Intervention: None. MEASUREMENTS AND MAIN RESULTS: The outcomes of patients treated with Cryo and FFP were compared with those treated with FFP only using propensity score-matching analysis. The dose of administered clotting factors in each group was balanced. The primary outcome was inhospital mortality, and the secondary outcome was the occurrence rate of adverse events. A total of 24, 002 patients (Cryo+FFP group: 6, 018; FFP only group: 17, 984) were eligible for analysis, of whom 4, 852 propensity score-matched pairs were generated. Significantly lower inhospital mortality (1, 959 patients [40.4%] in the Cryo+FFP group vs 2, 142 patients [44.1%] in the FFP only group; odds ratio [OR], 0.86; 95% CI, 0.79–0.93) was observed in the Cryo+FFP group; no significant difference was observed in the occurrence rate of adverse events (1, 857 [38.3%] vs 1, 875 [38.6%]; OR, 1.02; 95% CI, 0.94–1.10). Several sensitivity analyses showed similar results. CONCLUSIONS: Cryo use combined with FFP was significantly associated with reduced mortality in bleeding trauma patients. Future randomized controlled trials are warranted to confirm these results.